A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary)
- Indications Carcinoma; Malignant thymoma
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2019 Planned number of patients changed from 24 to 55.
- 05 Feb 2019 Planned End Date changed from 30 Sep 2020 to 30 Sep 2021.
- 05 Feb 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.